Primary hyperoxaluria type 1: novel therapies at a glance

Area of Science:

• Biochemistry and Genetics
• Metabolic Disorders
• Pharmacology

Background:

• Primary hyperoxaluria (PH) encompasses genetic disorders of oxalate metabolism, including PH1, PH2, and PH3, leading to kidney stones and failure.
• Traditional PH treatments are supportive, involving hydration, inhibitors, and in some PH1 cases, vitamin B6, with transplantation as a last resort.
• PH1 results from AGXT gene mutations affecting alanine-glyoxylate aminotransferase (AGT); PH2 from GR/HPR mutations; PH3 from HOGA1 mutations.

Purpose of the Study:

• To review recent advancements in the treatment of primary hyperoxaluria, focusing on novel therapeutic strategies.
• To highlight the emergence of RNA interference (RNAi) therapies and other innovative approaches for managing PH.
• To discuss the potential impact of these new treatments on patient outcomes and future management paradigms.

Main Methods:

• Review of emerging therapies targeting oxalate metabolism in primary hyperoxaluria.
• Focus on RNA interference (RNAi) strategies targeting hepatic enzymes like glycolate oxidase (GO) and lactate dehydrogenase A (LDH-A).
• Exploration of pharmacological inhibitors and microbiome manipulation as alternative or complementary treatments.

Main Results:

• RNAi therapies (lumasiran, nedosiran) have demonstrated significant reductions in urinary oxalate excretion in PH1 patients.
• Lumasiran is approved for PH1; nedosiran is in clinical trials, showing potential for improved PH management.
• Long-term efficacy and safety data for RNAi therapies are still being established, but initial results are promising.

Conclusions:

• Hepatically targeted RNAi therapies represent a potential paradigm shift in PH1 treatment, potentially reducing the need for transplantation.
• Development of pharmacological inhibitors and microbiome-based strategies offers additional therapeutic avenues, particularly for resource-limited settings.
• A new era of PH treatment is emerging, requiring further evaluation to confirm long-term efficacy and safety.